BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Clinical Trials
2.6k
Trial Phases
5 Phases
Drug Approvals
280
Drug Approvals
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20255004
- Approval Date
- May 19, 2025
Recombinant human interferon beta-1b for injection
- Product Name
- 倍泰龙
- Approval Number
- 国药准字SJ20130094
- Approval Date
- Aug 24, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140940
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140941
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140939
- Approval Date
- Apr 25, 2023
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20180010
- Approval Date
- Apr 10, 2023
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (2060 trials with phase data)• Click on a phase to view related trials
An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
- Conditions
- Metastatic Hormonesensitive Prostate Cancer (mHSPC)
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1000
- Registration Number
- NCT07223372
BAY3401016; Biomarker Study Alport
- Conditions
- Alport Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT07211685
- Locations
- 🇺🇸
Nephrology Clinic at The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸The Peggy and Harold Katz Family Drug Discovery Center - Nephrology, Miami, Florida, United States
🇺🇸Center for Advanced Pediatrics - Nephrology, Atlanta, Georgia, United States
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
- Interventions
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 117
- Registration Number
- NCT07192952
- Locations
- 🇺🇸
Emory University Hospital - Children's Healthcare of Atlanta Cardiology - Atlanta, Atlanta, Georgia, United States
🇺🇸Riley Hospital For Children - Cardiology, Indianapolis, Indiana, United States
🇺🇸MUSC Shawn Jenkins Children's Hospital - Cardiology, North Charleston, South Carolina, United States
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 111
- Registration Number
- NCT07188805
- Locations
- 🇺🇸
St. Louis Children's Hospital - Cardiology, St Louis, Missouri, United States
🇺🇸Children's Hospital Colorado - Anschutz Medical Campus - Cardiology, Aurora, Colorado, United States
🇺🇸Nemours Children's Hospital -Delaware, Wilmington, Delaware, United States
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
- Conditions
- Sepsis Associated Disseminated Intravascular Coagulation (DIC)
- Interventions
- Drug: Matching Placebo / Diluent
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT07176728
- Locations
- 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Fukuoka Pref, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 329
- Next
News
Hemlibra Demonstrates Exercise-Related Bleeding Prevention in Hemophilia A as Pfizer Reports Positive Phase III BAISIS Results
Hemlibra has shown efficacy in preventing bleeding during exercise for patients with Hemophilia A, marking a significant advancement in activity-related bleeding management.
AstraZeneca Establishes Sixth Global R&D Center in Beijing to Accelerate AI-Driven Drug Discovery
AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.
Medherant's Testosterone Patch Shows Promise in Phase 1 Trial for Menopausal Women
Medherant's TEPI Patch successfully restored testosterone blood levels to normal pre-menopausal ranges in post-menopausal women during Phase 1 clinical testing at Hammersmith Medicines Research in London.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
AskBio Reports Positive Interim Safety Data for AB-1003 Gene Therapy in Rare Muscular Dystrophy Trial
AskBio presented interim safety results from the Phase 1/2 LION-CS101 trial showing no dose-limiting toxicities or serious adverse events for AB-1003 gene therapy in LGMD2I/R9 patients up to 52 weeks post-treatment.
Irish Court Invalidates Bayer's Rivaroxaban Dosing Patent in €3.5 Billion Xarelto Challenge
The High Court of Ireland ruled that Bayer's patent protecting once-daily dosing of rivaroxaban (Xarelto) was invalid for lack of inventive step, affecting a product worth €3.5 billion globally in 2024.
Federal Circuit Upholds Generic Challenge to Bayer's Xarelto Patent Protection
The Federal Circuit rejected Bayer's appeal to dismiss a patent validity challenge from three generic drug makers targeting the blockbuster blood-thinning drug Xarelto.
Shilpa Medicare Receives EMA Approval for Generic Rivaroxaban Orodispersible Films
Shilpa Medicare Limited has secured European Medicine Agency approval for its generic Rivaroxaban Orodispersible Films, a bioequivalent alternative to Bayer's Xarelto tablets.
European Regulators Recommend Approval for Novo Nordisk's Weekly Diabetes Combination Therapy Kyinsu
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Novo Nordisk's once-weekly injectable diabetes treatment Kyinsu for adults with type 2 diabetes.
Advanced Liver Cancer Pipeline Shows Robust Growth with 50+ Companies Developing Novel Therapies
DelveInsight's 2025 pipeline report reveals over 50 active companies developing 52+ advanced liver cancer therapies, indicating strong industry commitment to addressing this challenging malignancy.